Pollack Seth M, O'Connor Thomas P, Hashash Jana, Tabbara Imad A
Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.
Am J Clin Oncol. 2009 Dec;32(6):618-28. doi: 10.1097/COC.0b013e31817f9de1.
Allogeneic hematopoietic stem cell transplantation provides many patients, with hematological and malignant diseases, hope of remission and in some cases cure. Because the toxicities of this approach are severe, its use has been limited to younger healthier patients. Nonmyeloablative and reduced intensity conditioning regimens depend more on donor cellular immune effects and less on the cytotoxic effects of the conditioning regimen to eradicate the underlying disease. This approach is based on the induction of host tolerance to donor cells followed by the administration of scheduled donor T-lymphocytes infusions. Accumulated clinical data have been encouraging, and prospective studies are underway to compare this approach to conventional myeloablative allogeneic stem cell transplantation with regard to outcome, durability of responses, effects on the immune system, and the consequences of late complications such as chronic graft-versus-host disease.
异基因造血干细胞移植为许多患有血液系统疾病和恶性疾病的患者带来了缓解甚至在某些情况下治愈的希望。由于这种治疗方法的毒性很强,其应用一直局限于更年轻、健康状况更好的患者。非清髓性和减低强度预处理方案更多地依赖供体细胞免疫效应,而较少依赖预处理方案的细胞毒性效应来根除潜在疾病。这种方法基于诱导宿主对供体细胞的耐受性,随后定期输注供体T淋巴细胞。积累的临床数据令人鼓舞,目前正在进行前瞻性研究,以比较这种方法与传统清髓性异基因干细胞移植在疗效、反应持久性、对免疫系统的影响以及慢性移植物抗宿主病等晚期并发症后果方面的差异。